Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +45.22%
#3 Glidr Glidr +45.16%
#4 Cysic Cysic +25.83%
#5 Tutorial Tutorial +24.70%
#6 Walrus Walrus +24.17%
#7 Humanity Humanity +17.87%
#8 Enso Enso +17.09%
#9 Codatta Codatta +14.69%
#10 Huma Finance Huma Finance +14.16%
Coin of the day
EXOD EXOD
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Compugen Ltd. Compugen Ltd.

Compugen Ltd.

CGEN
शेयरों में रैंक #36946
Compugen Ltd. is a clinical-stage biotechnology company engaged in the... Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
शेयर मूल्य
$2.31
अंतिम समन्वयन: 2026-08-14
मार्केट कैप
$2.18M
बदलाव (1 दिन)
-3.16%
बदलाव (1 वर्ष)
57.79%
देश
IL
व्यापार Compugen Ltd. (CGEN)

श्रेणी

Healthcare
Compugen Ltd. (CGEN) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $2.30 (2026-08-01 को)

दिन का सबसे निम्न समापन मूल्य: $1.56 (2002-08-01 को)
Compugen Ltd. के स्टॉक मूल्य का इतिहास 2002 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
वर्ष प्रदर्शन
2026 (TTM) 26.26%
2025 -2.77%
2024 29.85%
2023 33.11%
2022 -79.00%
2021 -66.79%
2020 129.28%
2019 99.35%
2018 11.15%
2017 -55.10%
2016 -15.79%
2015 -15.30%
2014 -10.13%
2013 75.91%
2012 8.18%
2011 8.07%
2010 24.89%
2009 613.45%
2008 -72.15%
2007 -34.57%
2006 -11.38%
2005 -36.97%
2004 -8.96%
2003 215.42%
2002 0.00%
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
कंपनी स्टॉक मूल्य परिवर्तन 1व% देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE